{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:58Z","timestamp":1792786138453,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Regional Innovation System & Education (RISE) program through the Gyeongbuk RISE CENTER, funded by the Ministry of Education (MOE) and the Gyeongsangbuk-do, Republic of Korea","award":["2025-RISE-15-107"],"award-info":[{"award-number":["2025-RISE-15-107"]}]},{"name":"Catholic University of Daegu","id":[{"id":"https:\/\/ror.org\/04fxknd68","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate hepatic adverse event reporting associated with fezolinetant after regulatory approval and the U.S. Food and Drug Administration\u2019s (FDA) boxed warning using data from the FDA Adverse Event Reporting System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective disproportionality analysis using the FDA\u2019s Adverse Event Reporting System database from the second quarter of 2023 through the second quarter of 2025. Reporting odds ratios and 95% CIs were calculated. We performed subgroup analyses, comparative hepatic adverse event assessments against reference drugs, and time-to-onset analyses using the Weibull distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Among 1,282 fezolinetant-associated reports, a hepatic adverse event reporting signal was identified and was predominantly associated with liver enzyme elevations rather than clinically overt hepatic injury. Marked disproportionality was observed in alanine aminotransferase, aspartate aminotransferase, and liver function testing increases. Compared with reference hepatotoxic drugs and hormone therapy agents, fezolinetant was associated with higher reporting signals for laboratory-based abnormalities; however, clinically severe hepatic outcomes were less consistently observed. Median time-to-onset for hepatic events was 77 days (IQR: 30\u2013149), with a Weibull shape parameter consistent with an early failure pattern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Data identify a signal of hepatic adverse event reporting for fezolinetant, primarily characterized by transaminase elevations rather than clinically overt liver injury. The early failure pattern suggests that hepatic events may tend to occur relatively early after treatment initiation, which highlights the importance of baseline assessment and early-phase monitoring, but continued clinical vigilance remains warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006331","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:01:27Z","timestamp":1780002087000},"page":"e329-e337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic Adverse Event Signals of Fezolinetant in Real-World Use Based on Postmarketing Surveillance"],"prefix":"10.1097","volume":"148","author":[{"given":"Nai","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeobin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"101819","DOI":"10.1016\/j.beem.2023.101819","article-title":"Non-oestrogen-based and complementary therapies for menopause","volume":"38","author":"Al Wattar","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/87551225231198700","article-title":"Fezolinetant: a new nonhormonal treatment for vasomotor symptoms","volume":"39","author":"Onge","year":"2023","journal-title":"J Pharm Technol"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1097\/MS9.0000000000001659","article-title":"Revolutionary treatment for menopausal symptoms: veozah (Fezolinetant) receives FDA approval","volume":"86","author":"Mughal","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/jcph.70070","article-title":"Pharmacokinetics and safety of fezolinetant in women with hepatic or renal impairment","volume":"65","author":"Iwai","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1210\/endo-128-5-2239","article-title":"Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women","volume":"128","author":"Rance","year":"1991","journal-title":"Endocrinology"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"108291","DOI":"10.1016\/j.bioorg.2025.108291","article-title":"Carbene reactive metabolite explains the hepatotoxicity of the hot flashes drug fezolinetant: a DFT investigation","volume":"157","author":"Nuthi","year":"2025","journal-title":"Bioorg Chem"},{"key":"R15-20261015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40780-019-0134-6","article-title":"Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)","volume":"5","author":"Nango","year":"2019","journal-title":"J Pharm Health Care Sci"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"e0314970","DOI":"10.1371\/journal.pone.0314970","article-title":"Oseltamivir-induced hepatotoxicity: a retrospective analysis of the FDA adverse event reporting system","volume":"20","author":"Yu","year":"2025","journal-title":"PLoS One"},{"key":"R17-20261015","doi-asserted-by":"crossref","first-page":"1473756","DOI":"10.3389\/fphar.2024.1473756","article-title":"Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023)","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"R18-20261015","doi-asserted-by":"crossref","first-page":"e33417","DOI":"10.1016\/j.heliyon.2024.e33417","article-title":"Adverse events associated with eteplirsen: a disproportionality analysis using the 2016-2023 FAERS data","volume":"10","author":"Dai","year":"2024","journal-title":"Heliyon"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ajd.13546","article-title":"Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta-analysis","volume":"62","author":"Azzam","year":"2021","journal-title":"Australas J Dermatol"},{"key":"R21-20261015","doi-asserted-by":"crossref","first-page":"e00847","DOI":"10.14309\/crj.0000000000000847","article-title":"Late-onset acute liver injury from azathioprine","volume":"9","author":"Schwartz","year":"2022","journal-title":"ACG Case Rep J"},{"key":"R22-20261015","doi-asserted-by":"crossref","first-page":"e260098","DOI":"10.1136\/bcr-2024-260098","article-title":"Drug-induced liver injury secondary to tamoxifen","volume":"17","author":"Subhaharan","year":"2024","journal-title":"BMJ Case Rep"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cld.765","article-title":"Noninvasive tests to monitor methotrexate-induced liver injury","volume":"13","author":"Labadie","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"keaf522","DOI":"10.1093\/rheumatology\/keaf522","article-title":"The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs","volume":"65","author":"Bechman","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00042737-200406000-00013","article-title":"Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance","volume":"16","author":"Elefsiniotis","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R26-20261015","doi-asserted-by":"crossref","first-page":"G49","DOI":"10.1093\/ejendo\/lvaf206","article-title":"European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause","volume":"193","author":"Lumsden","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12876-025-04154-w","article-title":"Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R28-20261015","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11096-025-01980-6","article-title":"Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database","volume":"47","author":"Tan","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"R29-20261015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf"},{"key":"R30-20261015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R31-20261015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R32-20261015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/GME.0000000000002354","article-title":"Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)","volume":"31","author":"Nappi","year":"2024","journal-title":"Menopause"},{"key":"R33-20261015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jcph.6157","article-title":"In vitro evaluation of CYP-mediated metabolism of fezolinetant and pharmacokinetic interaction between fezolinetant and fluvoxamine in healthy postmenopausal smokers and nonsmokers","volume":"65","author":"Iwai","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R34-20261015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJMc2412361","article-title":"Neurokinin-3 receptor antagonism for refractory hot flashes in men","volume":"392","author":"Lin","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:01:42Z","timestamp":1792069302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006331","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2026-01-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}